Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids

Jessica Pinheiro De Lucena-Thomas, Kimberley Luetchford (Editor), Marianne Ellis (Editor)

Research output: Contribution to conferencePoster


Around 95% of new drug candidates that are studied in humans fail
to be both effective and safe.1,2 Therefore, it is crucial to use better
predictive toxicology models to move towards more successful clinical
translation and consequently improve people`s lives by providing
better healthcare treatments.
 Simple models have been used previously, such as 2D monolayer
cultures, 3D spheroids cultures and tissue explants, but all of these
present a large gap between the cellular level and the organ level.3
The development of a 3D model called organoids has provided a
better in vitro biological model with the potential to improve the
drug discovery process. They can better predict drug efficacy and
toxicity, while reducing the need for animal models in the drug discovery
pipeline. In this context, Cellesce has developed a new bioprocessing technology
for large scale expansion of organoids, ensuring that there are enough organoids of high quality to enable their application by the pharmaceutical industry. This project analyzed the product, by size and number, using three techniques, improved the organoid expansion process.
Original languageEnglish
Publication statusPublished - 10 Jul 2017
EventCSCT Summer Showcase 2017: Sustainable Chemical Technologies for a Circular Economy - Bath, UK United Kingdom
Duration: 10 Jul 201711 Jul 2017


ConferenceCSCT Summer Showcase 2017
Country/TerritoryUK United Kingdom
Internet address


Dive into the research topics of 'Colorectal Cancer Organoid Expansion for Drug Discovery: Method Selection for Analysing Organoids'. Together they form a unique fingerprint.

Cite this